Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.68 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.46 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5100586 | 0.92 | HRH3 (0.70) | HRH3KCNA5GAAHRH2HRH1 | |
| SCHEMBL14287747 | 0.81 | HRH3 (1.00) | HRH3GAAHRH1 | |
| SCHEMBL5093846 | 0.81 | HRH3 (1.00) | HRH3GAAHRH1 | |
| SCHEMBL6109481 | 0.80 | HRH3 (0.66) | HRH3KCNA5 | |
| SCHEMBL5100971 | 0.78 | HRH3 (0.62) | HRH3S1PR5ABHD6 | |
| SCHEMBL5097371 | 0.74 | HRH3 (1.00) | HRH3S1PR5 | |
| Hydrochloric Acid SCHEMBL5935388 | 0.73 | HRH1 (0.68) | HRH3KCNA5HRH2HRH1 | |
| SCHEMBL5773186 | 0.72 | HRH3 (0.47) | HRH3S1PR5ABHD6 | |
| SCHEMBL5100684 | 0.71 | HRH3 (0.62) | HRH3S1PR5 | |
| SCHEMBL5093782 | 0.70 | HRH3 (1.00) | HRH3S1PR5HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7314937-B2 | Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314937-B2 | Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314937-B2 | Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-20040110748-A1 | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses | BEAVERS LISA SELSAM (US) | 2004-06-10 | — | — | US | disclosed |
| EP-1379493-A2 | NON-IMIDAZOLE ARYL ALKYLAMINES COMPOUNDS AS HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | Eli Lilly and Company (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002076925-A2 | NON-IMIDAZOLE ARYL ALKYLAMINES COMPOUNDS AS HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110748-A1 | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses | HRH3, HRH4, HRH2 | HRH3 1/4885KCNA5 979/4885GAA 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.